UK -Siemens Healthineers, a global leader in medical technology, has announced a £250 million (  US$ 313.7million ) investment in a state-of-the-art production facility in the United Kingdom. 

This cutting-edge facility, slated to commence operations in 2026, is poised to revolutionize the manufacturing of Magnetic Resonance Imaging (MRI) devices, addressing critical industry challenges while creating over 1,300 job opportunities in North Oxfordshire.

The facility stands as a beacon of innovation, incorporating Siemens Healthineers’ innovative DryCool technology. 

This breakthrough approach drastically reduces helium consumption in MRI scanners from a staggering 1,500 liters to under a single liter, thereby alleviating strain on limited and unsustainable resources. 

By championing DryCool technology, Siemens Healthineers not only pioneers environmental sustainability but also enhances accessibility to MRI diagnostics for a broader patient demographic.

Bernd Montag, Chief Executive Officer of Siemens Healthineers, emphasized the pivotal role of MRI technology in healthcare, stating, “MRI technology plays a vital role in diagnosing disease, helping patients to get healthy and stay healthy.” 

He further underscored the significance of the new facility, heralding it as the global epicenter for innovative low-helium magnet technology, poised to revolutionize MRI accessibility worldwide.

Moreover, the facility will serve as a nucleus for research and development, spearheading advancements in medical imaging. 

Siemens Healthineers aims to leverage the site to design and manufacture cutting-edge whole-body scanners, renowned for their compactness and portability, facilitating enhanced patient care globally.

UK Prime Minister Rishi Sunak hailed the unveiling of the facility as a testament to British innovation and a boon to the regional economy. 

He lauded the creation of over 1,300 skilled jobs in Oxfordshire, underscoring the region’s prowess in healthcare and research and development. 

Sunak emphasized the global impact of the facility, highlighting its role in advancing patient care on a global scale.

This milestone achievement follows Siemens Healthineers’ strategic decision to pivot towards innovation-driven ventures, exemplified by the closure of its fast-track diagnostics arm. 

Furthermore, it builds upon the recent approval from the US Food and Drug Administration (FDA) for Siemens Healthineers’ MAGNETOM Cima.X 3 Tesla MRI device, reaffirming the company’s commitment to pioneering medical advancements.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook